Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG1042 intratumoral therapy in cutaneous T-cell and B-cell lymphomas
DRKS00000219Phase 2Completed
- Sponsor
- Transgene SA
- Start
- Nov 2009
- Modality
- Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label trial of TG1042 in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), cutaneous B-cell lymphoma (CBCL) and 2 more (5 cohorts), sponsored by Transgene SA. Started Nov 2009; status: completed.
02
Drugs
TG1042
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)cutaneous B-cell lymphoma (CBCL)peripheral T cell lymphomas (PTCL)mature B-cell lymphoma
Beyond the preview
Go deeper on DRKS00000219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000219.